BACKGROUND: Mesenchymal stem cells (MSCs) are non-hematopoietic, adult, fibroblast-like, multipotent cells that are plastic adherent in standard culture conditions. They can be isolated from several tissues, but it is always necessary to expand them for clinical practice. AIM: We investigated the effect of human platelet lysate (hPL) on the expansion of human MSCs isolated from adipose tissue (AT), comparing it with fetal bovine serum (FBS) and human platelet-poor plasma (hPPP). MATERIALS AND METHODS: Human AT-MSCs, hPL and hPPP were obtained from 7 healthy subjects. AT-MSCs were seeded at 1500 cells/cm(2) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 10% hPPP or 10% hPL. Cells were harvested, counted and analyzed by flow cytometry every 7 days for 5 passages (P). The differentiation assays, RNA isolation and co-culture with allogeneic lymphocytes were performed at the end of P2. RESULTS: AT-MSCs achieved a better proliferation rate when cultured with hPL than with hPPP or FBS (20 ±2 versus 8 ±3 and 6 ±3, respectively, at the end of P5 [p<0.01]). hPL preserved the differentiation capacity and typical expression of surface antigens, avoiding the risks associated with the use of animal derivatives. AT-MSCs demonstrated a stronger inhibitory effect on lymphocyte proliferation with hPL than with other culture conditions, even at a AT-MSCs:T cells ratio of 1:10. The transcriptional level of matrix metalloproteinase 2, used to evaluate stemness, was very high in all conditions tested. CONCLUSIONS: hPL represents an effective and safe supplement for MSC expansion to be used in the clinical setting.
BACKGROUND: Mesenchymal stem cells (MSCs) are non-hematopoietic, adult, fibroblast-like, multipotent cells that are plastic adherent in standard culture conditions. They can be isolated from several tissues, but it is always necessary to expand them for clinical practice. AIM: We investigated the effect of human platelet lysate (hPL) on the expansion of human MSCs isolated from adipose tissue (AT), comparing it with fetal bovine serum (FBS) and human platelet-poor plasma (hPPP). MATERIALS AND METHODS:Human AT-MSCs, hPL and hPPP were obtained from 7 healthy subjects. AT-MSCs were seeded at 1500 cells/cm(2) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 10% hPPP or 10% hPL. Cells were harvested, counted and analyzed by flow cytometry every 7 days for 5 passages (P). The differentiation assays, RNA isolation and co-culture with allogeneic lymphocytes were performed at the end of P2. RESULTS: AT-MSCs achieved a better proliferation rate when cultured with hPL than with hPPP or FBS (20 ±2 versus 8 ±3 and 6 ±3, respectively, at the end of P5 [p<0.01]). hPL preserved the differentiation capacity and typical expression of surface antigens, avoiding the risks associated with the use of animal derivatives. AT-MSCs demonstrated a stronger inhibitory effect on lymphocyte proliferation with hPL than with other culture conditions, even at a AT-MSCs:T cells ratio of 1:10. The transcriptional level of matrix metalloproteinase 2, used to evaluate stemness, was very high in all conditions tested. CONCLUSIONS:hPL represents an effective and safe supplement for MSC expansion to be used in the clinical setting.
Authors: Ruurd Torensma; Henk-Jan Prins; Ellen Schrama; Eugène T P Verwiel; Anton C M Martens; Helene Roelofs; Bastiaan J H Jansen Journal: Stem Cells Dev Date: 2012-12-21 Impact factor: 3.272
Authors: Amel Dudakovic; Emily Camilleri; Scott M Riester; Eric A Lewallen; Sergiy Kvasha; Xiaoyue Chen; Darcie J Radel; Jarett M Anderson; Asha A Nair; Jared M Evans; Aaron J Krych; Jay Smith; David R Deyle; Janet L Stein; Gary S Stein; Hee-Jeong Im; Simon M Cool; Jennifer J Westendorf; Sanjeev Kakar; Allan B Dietz; Andre J van Wijnen Journal: J Cell Biochem Date: 2014-10 Impact factor: 4.429
Authors: B A Naaijkens; H W M Niessen; H-J Prins; P A J Krijnen; T J A Kokhuis; N de Jong; V W M van Hinsbergh; O Kamp; M N Helder; R J P Musters; A van Dijk; L J M Juffermans Journal: Cell Tissue Res Date: 2012-03-07 Impact factor: 5.249
Authors: Maria C Naskou; Scarlett M Sumner; Anna Chocallo; Hannah Kemelmakher; Merrilee Thoresen; Ian Copland; Jacques Galipeau; John F Peroni Journal: Stem Cell Res Ther Date: 2018-03-22 Impact factor: 6.832
Authors: Mahmoud A Saeed; Mohamed Abd El-Rahman; Mohamed E Helal; Ahmed R Zaher; Mohammed E Grawish Journal: Int J Stem Cells Date: 2017-05-30 Impact factor: 2.500